Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

X

Reynald Castaneda

18 Jun 2021

Comment

LoA Update: Terns’ FXR agonist asset jumps by 16 points on chances to move to next stage in NASH after Phase IIa data announcement

18 Jun 2021

17 Jun 2021

Comment

Post-ASCO News Alert: Merck’s KEYNOTE-564 data heralds early adjuvant Keytruda use in renal cancer

17 Jun 2021

17 Jun 2021

Comment

LoA Update: Aclaris’ topical JAK inhibitor in moderate-to-severe atopic dermatitis approval likelihood soars by 22 points after topline Phase IIa data announcement

17 Jun 2021

16 Jun 2021

Comment

LoA Update: Amgen’s bemarituzumab approval likelihood in gastroesophageal junction and gastric cancers jumps after Phase II ASCO reveal

16 Jun 2021

11 Jun 2021

Comment

Post-ASCO News Alert: Seagen/Astellas’ Padcev has shot at Phase III success in 1L and FDA approval in 2L urothelial carcinoma, although spoilers notable

11 Jun 2021

11 Jun 2021

Comment

Post-ASCO News Alert: Clovis’ Phase III Rubraca trial in 2L castrate-resistant prostate cancer recruits 351 of 400-patient target; patients hard to find and long wait for test results

11 Jun 2021

11 Jun 2021

Comment

LoA Update: Shanghai Fosun’s FN-1501 approval likelihood in refractory AML drop by five points, relapsed AML by seven points after Phase I update

11 Jun 2021

11 Jun 2021

Comment

LoA Update: Sanofi’s KY1044 approval chances jumps by 21 points after Phase I/II ASCO data reveal in triple-negative breast cancer

11 Jun 2021

09 Jun 2021

Comment

LoA Update: Cytokinetics’ omecamtiv mecarbil transition to next development stage in paediatric heart failure drops by six points after Amgen decoupling

09 Jun 2021

09 Jun 2021

Comment

LoA Update: AstraZeneca’s AZD2811 approval chances in refractory acute myeloid leukaemia decrease by one point after Phase I/II trial listed as completed

09 Jun 2021